An Open-Label, multicenter study in male pediatric patients with cerebral x-linked adrenoleukodystrophy (cald) to assess the effects of MIN-102 treatment on disease progression prior to human stem cell transplant (HSCT)

Inclusion Criteria:

• Males aged ≥2 and ≤12 years with a diagnosis of X-linked ALD
• White matter involvement as determined by cerebral MRI lesions without Gd enhancement at baseline (Population 1), or with Gd enhancement at baseline (Population 2).
• Major Functional Disabilities (MFD) score of 0.
• Baseline Loes score >0 and ≤10
• Gadolinium Intensity Score >2

Exclusion Criteria:

• Previous HSCT
• Too far progressed inflammatory brain lesions